Pfizer Investor Presentation — March 2018

Document content

Cowen and Company Health Care Conference

Global President, Pfizer Oncology

Forward Looking Statements

This presentation includes forward-looking statements about, among other things,

Pfizer’s oncology in-line products and product candidates, including anticipated regulatory submissions, approvals, performance and potential benefits of Pfizer's oncology products and product candidates, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

Additional information regarding these factors can be found in Pfizer’s Annual

Report on Form 10-K for the fiscal year ended December 31, 2017 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward -Looking Information and Factors that May Affect

Future Results”, as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission (SEC) and available at www.sec.gov and www.pfizer.com.

The forward-looking statements in this presentation speak only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements. 3

Pfizer Oncology Growth Trajectory

Growing in- line portfolio f ueled by IBRANCE & XTANDI with

potential for multiple launches on the horizon

Curve is for illustrative purposes only

*numbers for 2018- 2020 reflect potential approvals and indications that are expected and may not materialize Opportunistic & Niche Growth & Leadership Mindset

TALAZOPARIB DACOMITINIB

Medicines* 2 3 5 5 5 6 7 10 12 14 14

# Approved Indications* 3 5 7 8 8 9 11 17 20 21 28 E* E* E* 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020Revenue $B 4